BACKGROUND: Gene expression studies have identified distinct breast cancer subtypes, including luminal A, luminal B, Her2-enriched, and Basal-like, which differ in survival. The impact of subtypes on locoregional recurrence (LRR) after neoadjuvant chemotherapy for locally advanced breast cancer is unknown. METHODS: A total of 149 patients with stage II and III breast cancer with known ER, PR, and HER2 who underwent neoadjuvant chemotherapy from 1991 to 2005 were analyzed. We used clinical assays to distinguish luminal A (ER or PR+/HER2-, n = 55), luminal B (ER or PR+/HER2+, n = 25), HER2 (ER and PR-/HER2+, n = 20), and Basal-like (ER, PR, and HER2-, n = 49) subtypes. Covariates associated with LRR were evaluated by logistic regression and differences between subtypes tested using Wald χ(2). RESULTS: Median follow-up was 55 months. Forty-nine (33%) patients had breast conservation (BCT) with radiation, 82 (55%) had a mastectomy with radiation, and 18 (12%) had a mastectomy alone. Eighty-eight (59%) were clinically node positive. A pathologic complete response was seen in 39 (26%) patients. LRR was identified in 11 (7%) patients: 2 after BCT (4%) and 9 after mastectomy (9%). LRR rates by subtype are as follows: luminal A 2 of 55 (4%), luminal B 1 of 25 (4%), Her2 1 of 20 (5%), and basal-like 7 of 49 (14%). Compared with all other subtypes, basal-like patients were more likely to have a LRR (7/49 (14%) vs. 4/100 (4%), p = 0.03). CONCLUSIONS: Molecular subtype predicts LRR with basal-like patients more likely to develop LRR. These patients may be candidates for investigation with novel chemotherapy regimens and radiation sensitizing agents, which may offer improvement in local control.
BACKGROUND: Gene expression studies have identified distinct breast cancer subtypes, including luminal A, luminal B, Her2-enriched, and Basal-like, which differ in survival. The impact of subtypes on locoregional recurrence (LRR) after neoadjuvant chemotherapy for locally advanced breast cancer is unknown. METHODS: A total of 149 patients with stage II and III breast cancer with known ER, PR, and HER2 who underwent neoadjuvant chemotherapy from 1991 to 2005 were analyzed. We used clinical assays to distinguish luminal A (ER or PR+/HER2-, n = 55), luminal B (ER or PR+/HER2+, n = 25), HER2 (ER and PR-/HER2+, n = 20), and Basal-like (ER, PR, and HER2-, n = 49) subtypes. Covariates associated with LRR were evaluated by logistic regression and differences between subtypes tested using Wald χ(2). RESULTS: Median follow-up was 55 months. Forty-nine (33%) patients had breast conservation (BCT) with radiation, 82 (55%) had a mastectomy with radiation, and 18 (12%) had a mastectomy alone. Eighty-eight (59%) were clinically node positive. A pathologic complete response was seen in 39 (26%) patients. LRR was identified in 11 (7%) patients: 2 after BCT (4%) and 9 after mastectomy (9%). LRR rates by subtype are as follows: luminal A 2 of 55 (4%), luminal B 1 of 25 (4%), Her2 1 of 20 (5%), and basal-like 7 of 49 (14%). Compared with all other subtypes, basal-like patients were more likely to have a LRR (7/49 (14%) vs. 4/100 (4%), p = 0.03). CONCLUSIONS: Molecular subtype predicts LRR with basal-like patients more likely to develop LRR. These patients may be candidates for investigation with novel chemotherapy regimens and radiation sensitizing agents, which may offer improvement in local control.
Authors: Philip M Spanheimer; Allison W Lorenzen; James P De Andrade; Mikhail V Kulak; Jennifer C Carr; George W Woodfield; Sonia L Sugg; Ronald J Weigel Journal: Ann Surg Oncol Date: 2015-05-14 Impact factor: 5.344
Authors: Zhongli Cai; Simmyung Yook; Yijie Lu; Dane Bergstrom; Mitchell A Winnik; Jean-Philippe Pignol; Raymond M Reilly Journal: Pharm Res Date: 2016-12-16 Impact factor: 4.200
Authors: T Jonathan Yang; Monica Morrow; Shanu Modi; Zhigang Zhang; Kate Krause; Chun Siu; Beryl McCormick; Simon N Powell; Alice Y Ho Journal: Ann Surg Oncol Date: 2015-07-01 Impact factor: 5.344
Authors: Nataliya Babyshkina; Elena Malinovskaya; Stanislav Patalyak; Olga Bragina; Natalia Tarabanovskaya; Artem Doroshenko; Elena Slonimskaya; Vladimir Perelmuter; Nadejda Cherdyntseva Journal: Med Oncol Date: 2014-08-20 Impact factor: 3.064
Authors: Xuanmao Jiao; Marco A Velasco-Velázquez; Min Wang; Zhiping Li; Hallgeir Rui; Amy R Peck; James E Korkola; Xuelian Chen; Shaohua Xu; James B DuHadaway; Sandra Guerrero-Rodriguez; Sankar Addya; Daniela Sicoli; Zhaomei Mu; Gang Zhang; Andres Stucky; Xi Zhang; Massimo Cristofanilli; Alessandro Fatatis; Joe W Gray; Jiang F Zhong; George C Prendergast; Richard G Pestell Journal: Cancer Res Date: 2018-01-22 Impact factor: 12.701
Authors: M E Law; P E Corsino; S C Jahn; B J Davis; S Chen; B Patel; K Pham; J Lu; B Sheppard; P Nørgaard; J Hong; P Higgins; J-S Kim; H Luesch; B K Law Journal: Oncogene Date: 2012-04-30 Impact factor: 9.867
Authors: Philip M Spanheimer; Jennifer C Carr; Alexandra Thomas; Sonia L Sugg; Carol E H Scott-Conner; Junlin Liao; Ronald J Weigel Journal: Am J Surg Date: 2013-01-31 Impact factor: 2.565
Authors: Judy C Boughey; Linda M McCall; Karla V Ballman; Elizabeth A Mittendorf; Gretchen M Ahrendt; Lee G Wilke; Bret Taback; A Marilyn Leitch; Teresa Flippo-Morton; Kelly K Hunt Journal: Ann Surg Date: 2014-10 Impact factor: 12.969